These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12127663)

  • 1. Immunomodulatory treatment of MS in Slovenia.
    Sega-Jazbec S
    Clin Neurol Neurosurg; 2002 Jul; 104(3):249-50. PubMed ID: 12127663
    [No Abstract]   [Full Text] [Related]  

  • 2. Newer long-term treatments for multiple sclerosis.
    Pryse-Phillips W
    Clin Neurol Neurosurg; 2002 Jul; 104(3):265-71. PubMed ID: 12127666
    [No Abstract]   [Full Text] [Related]  

  • 3. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
    Gusev EI; Boĭko AN; Pozer Ch
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
    [No Abstract]   [Full Text] [Related]  

  • 4. To treat, or not to treat: the therapeutic dilemma of idiopathic monosymptomatic demyelinating syndromes.
    Frohman EM; Racke M; van Den Noort S
    Arch Neurol; 2000 Jul; 57(7):930-2. PubMed ID: 10891973
    [No Abstract]   [Full Text] [Related]  

  • 5. Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.
    Yong VW
    Neurology; 2002 Sep; 59(6):802-8. PubMed ID: 12349849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
    Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
    Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Possibilities and limits of immunotherapy in multiple sclerosis. Inflammatory and degenerative aspects of the disease require a new pathogenetic concept].
    Kornhuber ME; Zierz S
    Nervenarzt; 2003 Jun; 74(6):537-8; discussion 539. PubMed ID: 12799792
    [No Abstract]   [Full Text] [Related]  

  • 8. [A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
    Zavalishin IA; Peresedova AV; Stoĭda NI; Rebrova Oi; Zakharova MN; Adarcheva LS; Niazbekova AS; Askarova LSh; Baĭdina EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; Spec No 3():111-5. PubMed ID: 17172245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Will there soon be a sub-type specific treatment? New approaches to multiple sclerosis therapy].
    MMW Fortschr Med; 2008 Apr; 150(15):17. PubMed ID: 18510111
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunologic therapy for secondary and primary progressive multiple sclerosis.
    Myers LW
    Curr Neurol Neurosci Rep; 2001 May; 1(3):286-93. PubMed ID: 11898531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience.
    Ghezzi A; Amato MP; Annovazzi P; Capobianco M; Gallo P; La Mantia L; Marrosu MG; Martinelli V; Milani N; Moiola L; Patti F; Pozzilli C; Trojano M; Zaffaroni M; Comi G;
    Neurol Sci; 2009 Jun; 30(3):193-9. PubMed ID: 19387545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Newer versus older treatments for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B; Cohen JA
    Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Why treat early multiple sclerosis patients?
    Comi G
    Curr Opin Neurol; 2000 Jun; 13(3):235-40. PubMed ID: 10871245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current concepts on the use of some immunomodulatory drugs in the treatment of multiple sclerosis].
    Correale J; Cristiano E
    Medicina (B Aires); 2001; 61(4):470-80. PubMed ID: 11563177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug therapy of multiple sclerosis].
    Kinnunen E
    Duodecim; 1999; 115(4):403-7. PubMed ID: 11830889
    [No Abstract]   [Full Text] [Related]  

  • 16. The use of interferon Beta and glatiramer acetate in multiple sclerosis.
    Goodin DS
    Semin Neurol; 2013 Feb; 33(1):13-25. PubMed ID: 23709209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiple sclerosis (MS), an inflammatory or degenerative disease?].
    Confavreux C; Vukusic S
    Presse Med; 2004 Feb; 33(3):151-2. PubMed ID: 15029024
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunologic therapy for relapsing-remitting multiple sclerosis.
    MacLean HJ; Freedman MS
    Curr Neurol Neurosci Rep; 2001 May; 1(3):277-85. PubMed ID: 11898530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glatiramer and suspected multiple sclerosis. No proven advantage.
    Prescrire Int; 2010 Aug; 19(108):160. PubMed ID: 20941852
    [No Abstract]   [Full Text] [Related]  

  • 20. Current and investigational therapies used to alter the course of disease in multiple sclerosis.
    Miller A
    South Med J; 1997 Apr; 90(4):367-75. PubMed ID: 9114824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.